Skip to content
Pharma Observatory a Scientist.com platform

Organization (Hospital)

Helse Møre og Romsdal HF

ClinicalTrials.gov lists Helse Møre og Romsdal HF as lead sponsor of 24 trials. It has 11 active development programs and 1 approved asset.

NO Hospital
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

5 0 2011 2026

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 5 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 3.2 trial starts a year over the five years to September, under the 5 a year the method needs.

This page covers Helse Møre og Romsdal HF: 24 lead-sponsored trials and 1 legal-entity registration.

Get the Helse Møre og Romsdal HF report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (80)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Osteoarthritis 5
Osteoarthritis, Knee 4
Fractures, Bone 3
Hip Fractures 3
Amyloidosis 2

Trials by start year as sponsor or collaborator (13)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 5
2025 3
2024 4
2023 2
2022 3
2021 1
2020 3
2019 4
2018 5
2017 5

Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 14 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (11)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
(R,S)-ketamine (Pilot I) Rotator Cuff Injuries Phase 2/3 1
NaCl 9% Chronic Pain Phase 2/3 1
NaCl 9% Pain Phase 2/3 1
NaCl 9% Rotator Cuff Injuries Phase 2/3 1
(R,S)-ketamine (Pilot I) Pain Phase 2/3 1

Approved assets (1)

Approved assets
Drug Trials
(R,S)-ketamine (Pilot I) 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
54% hit target (n=13) 25% on time (n=12)

Journals published in (94)

Shown in this order: most published in first.

Journals published in
Journal Publications
Acta orthopaedica 11
Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA 6
The Journal of arthroplasty 5
The bone & joint journal 5
Clinical orthopaedics and related research 4

Organization relationships (71)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
Norwegian University of Science and Technology Co sponsors trial with 8
St. Olavs Hospital Co sponsors trial with 6
Vestre Viken Hospital Trust Co sponsors trial with 5
Akershus University Hospital Co sponsors trial with 5
Haukeland University Hospital Co sponsors trial with 5

Latest dated events (54)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-10-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-17 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-01 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-05-21 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-01-09 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))

Biomarker capability evidence (14)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
CBS Trial collaborator Named in trial inclusion criteria
DBT Trial sponsor Named in trial inclusion criteria
ELN Trial collaborator Named in trial inclusion criteria
MUC16 Trial collaborator Named in trial inclusion criteria
TNF Trial sponsor Named in trial inclusion criteria

Biomarkers this organization publishes on (16)

Shown in this order: most publications first.

Biomarkers this organization publishes on
Biomarker Publications
ABCD2 1
ACE 1
ADIPOQ 1
ALB 1
AP2B1 1

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.